US › Healthcare

LeonaBio, Inc. (LONA)

US · Healthcare · Biotechnology

$6.95+2.36%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-19.0M

EPS

$-0.80

EPS estimate

$-1.90

EPS came in at -0.80 against a street estimate of -1.90 — a beat of 57.9%.

Key statistics

Market cap

$65.2M

Forward P/E

0.0

P/B

1.92

Book value

$3.57

EPS (TTM)

$-23.21

52-week high

$14.21

52-week low

$3.55

50-day MA

$7.89

200-day MA

$7.54

Beta

2.05

Analyst view

with an average price target of $17.33.

Shareholding

Insiders

4.49%

Institutions

87.66%

Largest institutional holders

Fund	Stake
Perceptive Advisors LLC	19.73%
Kalehua Capital Management LLC	8.36%
ADAR1 Capital Management LLC	7.72%
COMMODORE CAPITAL LP	4.93%
TCG Crossover Management, LLC	4.93%
NEA Management Company, LLC	4.93%
Spruce Street Capital LP	4.18%
Adage Capital Partners Gp LLC	3.18%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for LeonaBio, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.